TrialEuropean heart journal2018

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.

Brian A Ference et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.